Study of effectiveness and safety of roxadustat for renal anemia in dialysis patients

Study of effectiveness and safety of roxadustat for renal anemia in dialysis patients - roxadustat study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039234

Enrollment

Registered

2020-02-01

Start date

2020-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia in dialysis patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Any of our maintenance hemodialysis patients with no improvement in anemia after existing treatment for various causes and serum ferritin >= 300 ng/ml, epoetin kappa dose >= 9000 international units/week, darbepoetin alpha dose >= 40 micrograms/week, or epoetin beta pegol dose >=150 micrograms/four weeks.

Exclusion criteria

Exclusion criteria: Patient with thromboembolism within 6 months after treatment, malignant tumor during treatment, eye disease during treatment, and moderate or higher liver dysfunction.

Design outcomes

Primary

Measure	Time frame
Hb(evaluated before administration and 4, 12, and 24 weeks after administration)	—

Secondary

Measure	Time frame
Blood test(MCV,MCH,MCHC,reticulocyte count,erythropoietin,serum iron,ferritin,TIBC and TSAT),blood pressure,activity(frail checklist prepared by the Ministry of Health, Labor and Welfare)and digestive symptoms(Gastrointestinal Symptom Rating Scale). All evaluated before administration and 4, 12, and 24 weeks after administration.	—

Countries

Japan

Contacts

Public ContactJunki Aikawa

Nagakubo Hospital Dr

shiki12070712@gmail.com042-571-2211

Outcome results